Key Takeaways:
- MRK stock has rallied around 60% over the past year, climbing from a 52-week low of $75 to near $120 today.
- Our model projects Merck stock could reach around $141 per share by late 2028, a 17% total return and roughly 6% annualized.
- Keytruda continues to earn new global approvals, but Merck’s near-term revenue growth is expected to remain modest relative to its recent stock performance.
What Happened?
Merck & Co. (MRK) has delivered one of the most impressive rallies in large-cap pharma over the past 12 months. The stock climbed from a 52-week low of $75 to nearly $120 today, a gain of around 60%.
Keytruda, Merck’s blockbuster cancer immunotherapy drug that works by helping the immune system recognize and attack tumor cells, has continued expanding into new indications. Investor sentiment has turned broadly constructive as that pipeline momentum has accumulated.
Q1 2026 results brought measured relief. Merck reported an adjusted loss per share of $1.28, but that beat the analyst consensus estimate of a $1.51 loss. The company also set full-year 2026 revenue guidance of $65.5 billion to $67.0 billion. However, that range landed slightly below the $67.6 billion Wall Street had expected, so some caution remains.
The clinical pipeline has delivered several wins in recent months. Merck and Kelun-Biotech’s lung cancer combination improved overall survival in a late-stage trial. The EU’s drug regulator recommended Keytruda combined with Padcev for certain bladder cancer patients. And Merck’s collaboration with Moderna showed their melanoma vaccine combination cut the risk of cancer spread at five years, according to Reuters.
Strategically, Merck is reshaping its structure for the longer term. The company announced a separate oncology business unit in February 2026. Merck also priced a $6 billion multi-tranche debt offering in May 2026 to fund ongoing operations and pipeline investment.
Here’s why Merck stock could offer solid capital returns through 2028 as its core business drivers support shareholder value.
What the Model Says for MRK Stock
We analyzed the upside potential for Merck stock based on its Keytruda-driven revenue base, expanding oncology pipeline, and consistent quarterly dividend that contributes meaningfully to total shareholder return.
Based on estimates of 5% annual revenue growth, 36% operating margins, and a normalized P/E multiple of 14x, the model projects Merck stock could rise from $120 to $141 per share.
That would be a 17% total return, or a 6% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for MRK stock:
1. Revenue Growth: 5.2%
Merck’s one-year revenue CAGR (compound annual growth rate, the smoothed average yearly growth rate) stands at around 1.3%. Its five-year CAGR is a more robust 6.3%, driven largely by Keytruda’s label expansions across cancer types. However, the company’s most recent full-year 2026 guidance came in below prior Street estimates.
Near-term growth faces headwinds from competitive pressures and the costs of separating the oncology business unit. Keytruda’s pipeline remains strong, but new approvals take time to translate into meaningful additional revenue. The guidance range signals that management is setting a measured pace for the near term.
Based on analysts’ consensus estimates, we used a 5% revenue growth assumption for MRK. This reflects Keytruda’s continued expansion into new cancer indications, balanced against near-term guidance conservatism and transition costs from the strategic oncology restructuring.
2. Operating Margins: 35.5%
Merck’s last-twelve-month EBIT margin stands at 37.3%, and its gross margin is a high 76.7%. These figures reflect strong pricing power across Merck’s branded pharmaceutical portfolio, which benefits from patent protection on Keytruda and other core drugs. High gross margins are common in branded pharma because R&D costs are spread over many years of commercial sales.
Continued clinical investment and the costs of creating a separate oncology unit are adding to operating expenses. Merck is advancing multiple late-stage programs, and each trial carries a meaningful cost. These factors are likely to keep margins slightly below their recent peak in the near term.
Based on analysts’ consensus estimates, we used a 35.5% operating margin assumption for MRK. This aligns with recent historical margin levels and accounts for ongoing R&D spending and restructuring-related costs tied to the oncology separation.
3. Exit P/E Multiple: 14.1x
MRK’s forward NTM (next twelve months) P/E (the price investors pay for each dollar of expected earnings) is around 19.5x. Merck also offers a 2.8% dividend yield, which contributes meaningfully to total return for income-oriented investors. The quarterly dividend for Q3 2026 was declared at $0.85 per share, according to Reuters.
Large-cap pharmaceutical companies with durable franchises and dividend histories typically trade at forward P/E multiples between 12x and 20x. Merck’s strong cash generation and consistent capital returns support a reasonable valuation anchor. But near-term earnings pressure from the guidance cut and business separation costs may keep the multiple from expanding.
Based on analysts’ consensus estimates, we used a 14.1x exit P/E multiple for MRK. This reflects a modest discount to the current forward P/E and accounts for potential near-term earnings variability as the oncology restructuring progresses.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for MRK stock through 2030 show varied outcomes based on Keytruda’s revenue trajectory and operating margin execution (these are estimates, not guaranteed returns):
- Low Case: Revenue declines slightly, and pipeline execution disappoints → (0.1%) annual returns
- Mid Case: Keytruda sustains moderate growth and margins hold steady → 1.7% annual returns
- High Case: New approvals accelerate revenue and margins recover → 3.2% annual returns
Going forward, MRK stock’s near-term trajectory depends heavily on Keytruda’s continued label expansions and Merck’s ability to manage its oncology restructuring without disrupting core operations.
The modest return projections across all scenarios reflect both the stock’s strong 60% run over the past year and the muted near-term revenue growth outlook. Investors who value Merck’s dividend and durable franchise should weigh those strengths against the risk of slower-than-expected earnings recovery.
See what analysts think about MRK stock right now (Free with TIKR) >>>
Should You Invest in Merck?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MRK, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track MRK alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze the stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
